5:01 PM
Apr 29, 2019
 |  BioCentury  |  Finance

Why liver disease newco Alentis is aiming for one of largest Swiss A rounds

BioMedPartners, BB Pureos Bioventures lead $12M first close for Basel start-up

Liver disease newco Alentis Therapeutics is starting off small with the first close of its series A round, but the additional capital it expects to raise over the next six months could give it the largest series A for a Swiss biotech since 2015.

Founded in the BaseLaunch incubator in Basel, Alentis Therapeutics AG announced it raised CHF12.5 million ($12.3 million) in a series A round co-led by BioMedPartners and BB Pureos Bioventures. Other new investors included BPI France, German High-Tech Gründerfonds (HTGF) and Schroder Adveq.

According to CEO Markus Ewert, the company is focused...

Read the full 453 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >